Sanofi Gsk Covid 19 Vaccine Trials News Today : Breaking News, Live Updates & Top Stories | Vimarsana

COVID-19 vaccine: Sanofi, GSK report robust immune response in early-stage trials
Monday s announcement, however, comes as a relief for Sanofi and GSK after they were forced last December to restart their trial and delay the launch of the shot when the vaccine showed a low immune response in older adults as a result of a weak antigen formulation
Reuters | May 17, 2021 | Updated 14:21 IST
An experimental COVID-19 vaccine developed by Sanofi and GlaxoSmithKline showed a robust immune response in early-stage clinical trial results, enabling them to move to a late-stage study, the French drugmaker said on Monday.
Sanofi and Britain s GSK said a global Phase III trial would start in the coming weeks and involve more than 35,000 adults, with the hope of seeing the vaccine approved by the fourth quarter after having initially targeted the first half of this year before a setback. ....

United States , United Kingdom , European Union , World Health , President Ursula , World Health Organization Backed , Covid 19 Vaccine , Sanofi Covid 19 Vaccine , Gsk Covid 19 Vaccine , Sanofi Gsk Covid 19 Vaccine , Covid 19 Vaccine Trials , Sanofi Covid 19 Vaccine Trials , Gsk Covid 19 Vaccine Trials , Sanofi Gsk Covid 19 Vaccine Trials , European Union Presi , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ஐரோப்பிய தொழிற்சங்கம் , உலகம் ஆரோக்கியம் , ப்ரெஸிடெஂட் உர்சூல ,